<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Big Data in Biomedicine on Big Data in Biomedicine</title>
    <link>https://biomedical-big-data.de/</link>
    <description>Recent content in Big Data in Biomedicine on Big Data in Biomedicine</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <copyright>&amp;copy; 2018</copyright>
    <lastBuildDate>Sun, 15 Oct 2017 00:00:00 +0200</lastBuildDate>
    <atom:link href="/" rel="self" type="application/rss+xml" />
    
    <item>
      <title>The fight against COVID-19</title>
      <link>https://biomedical-big-data.de/post/covex/</link>
      <pubDate>Fri, 24 Apr 2020 00:00:00 +0200</pubDate>
      
      <guid>https://biomedical-big-data.de/post/covex/</guid>
      <description>&lt;p&gt;To address the Coronavirus Disease-2019 (COVID-19) crisis, drug repurposing is an attractive approach that offers new therapeutic options through the identification of alternative usages for already approved drugs. Numerous research groups around the world are working on treatment options for COVID-19 and are joining efforts to identify drugs that can be repurposed. A promising strategy for identifying drugs is to use network and systems medicine approaches, which provide a comprehensive understanding of the infection mechanisms while not only focussing on the virus and its direct interaction partners, but also including the host protein interaction network. To aid in COVID-19 related drug repurposing, the Chair of Experimental Bioinformatics organized a hackathon to develop CoVex, a network and systems medicine platform that integrates virus-human interaction data for SARS-CoV-2 and SARS-CoV. CoVex supports researchers in interactive network medicine analysis, where they can bring in their expert knowledge to identify putative drug targets and drug repurposing candidates.&lt;/p&gt;

&lt;p&gt;More information: &lt;a href=&#34;https://www.exbio.de/exbio-vs-covid-part-1&#34; target=&#34;_blank&#34;&gt;https://www.exbio.de/exbio-vs-covid-part-1&lt;/a&gt;&lt;/br&gt;
The CoVex platform: &lt;a href=&#34;https://exbio.wzw.tum.de/covex&#34; target=&#34;_blank&#34;&gt;https://exbio.wzw.tum.de/covex&lt;/a&gt;&lt;/br&gt;
Animation video:&lt;/br&gt;&lt;/p&gt;

&lt;iframe width=&#34;640&#34; height=&#34;480&#34; src=&#34;https://www.youtube.com/embed/yK1rbFi5wW0&#34; frameborder=&#34;0&#34; allow=&#34;accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture&#34; allowfullscreen&gt;&lt;/iframe&gt;
</description>
    </item>
    
    <item>
      <title>Mass-spectrometry-based draft of the Arabidopsis proteome</title>
      <link>https://biomedical-big-data.de/publication/mergner-2020-mass/</link>
      <pubDate>Wed, 11 Mar 2020 00:00:00 +0100</pubDate>
      
      <guid>https://biomedical-big-data.de/publication/mergner-2020-mass/</guid>
      <description></description>
    </item>
    
    <item>
      <title>BiCoN: Network-constrained biclustering of patients and omics data</title>
      <link>https://biomedical-big-data.de/publication/lazareva-2020-bicon/</link>
      <pubDate>Wed, 01 Jan 2020 00:00:00 +0100</pubDate>
      
      <guid>https://biomedical-big-data.de/publication/lazareva-2020-bicon/</guid>
      <description></description>
    </item>
    
    <item>
      <title>De Novo Pathway Enrichment with KeyPathwayMiner</title>
      <link>https://biomedical-big-data.de/publication/alcaraz-2020-novo/</link>
      <pubDate>Wed, 01 Jan 2020 00:00:00 +0100</pubDate>
      
      <guid>https://biomedical-big-data.de/publication/alcaraz-2020-novo/</guid>
      <description></description>
    </item>
    
    <item>
      <title>EpiGEN: an epistasis simulation pipeline</title>
      <link>https://biomedical-big-data.de/publication/blumenthal-2020-epigen/</link>
      <pubDate>Wed, 01 Jan 2020 00:00:00 +0100</pubDate>
      
      <guid>https://biomedical-big-data.de/publication/blumenthal-2020-epigen/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Immunedeconv: An R Package for Unified Access to Computational Methods for Estimating Immune Cell Fractions from Bulk RNA-Sequencing Data</title>
      <link>https://biomedical-big-data.de/publication/sturm-2020-immunedeconv/</link>
      <pubDate>Wed, 01 Jan 2020 00:00:00 +0100</pubDate>
      
      <guid>https://biomedical-big-data.de/publication/sturm-2020-immunedeconv/</guid>
      <description></description>
    </item>
    
    <item>
      <title>In Silico Cell-Type Deconvolution Methods in Cancer Immunotherapy</title>
      <link>https://biomedical-big-data.de/publication/sturm-2020-silico/</link>
      <pubDate>Wed, 01 Jan 2020 00:00:00 +0100</pubDate>
      
      <guid>https://biomedical-big-data.de/publication/sturm-2020-silico/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Quantitative comparison of within-sample heterogeneity scores for DNA methylation data</title>
      <link>https://biomedical-big-data.de/publication/scherer-2020-quantitative/</link>
      <pubDate>Wed, 01 Jan 2020 00:00:00 +0100</pubDate>
      
      <guid>https://biomedical-big-data.de/publication/scherer-2020-quantitative/</guid>
      <description></description>
    </item>
    
    <item>
      <title>The mRNA-binding Protein TTP/ZFP36 in Hepatocarcinogenesis and Hepatocellular Carcinoma</title>
      <link>https://biomedical-big-data.de/publication/krohler-2019-mrna/</link>
      <pubDate>Fri, 01 Nov 2019 00:00:00 +0100</pubDate>
      
      <guid>https://biomedical-big-data.de/publication/krohler-2019-mrna/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Big data and its challenges on the path towards systems medicine</title>
      <link>https://biomedical-big-data.de/talk/insights2019/</link>
      <pubDate>Tue, 06 Aug 2019 00:00:00 +0200</pubDate>
      
      <guid>https://biomedical-big-data.de/talk/insights2019/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Network biology in the era of big data</title>
      <link>https://biomedical-big-data.de/talk/itarget/</link>
      <pubDate>Tue, 06 Aug 2019 00:00:00 +0200</pubDate>
      
      <guid>https://biomedical-big-data.de/talk/itarget/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Genome-wide endogenous RNA networks highlight novel biomarkers in cancer</title>
      <link>https://biomedical-big-data.de/talk/mccmb/</link>
      <pubDate>Wed, 31 Jul 2019 00:00:00 +0200</pubDate>
      
      <guid>https://biomedical-big-data.de/talk/mccmb/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Large-scale inference of competing endogeneous RNA networks with sparse partial correlation</title>
      <link>https://biomedical-big-data.de/talk/ismb2019/</link>
      <pubDate>Tue, 23 Jul 2019 00:00:00 +0200</pubDate>
      
      <guid>https://biomedical-big-data.de/talk/ismb2019/</guid>
      <description></description>
    </item>
    
    <item>
      <title>MOLIT Symposium 2019</title>
      <link>https://biomedical-big-data.de/post/molit-symposium/</link>
      <pubDate>Mon, 18 Mar 2019 00:00:00 +0100</pubDate>
      
      <guid>https://biomedical-big-data.de/post/molit-symposium/</guid>
      <description>

&lt;p&gt;The first MOLIT Symposium is actively promoting the dialogue of implementing personalized medicine into treatment routine. Therefore, a platform to interlink practicing physicians and IT experts is formed. This opens up possibilities to join forces between oncology and IT on problems in patient care to make solutions usable in everyday clinical practice.&lt;/p&gt;

&lt;h3 id=&#34;study-designs-for-personalized-medicine&#34;&gt;Study Designs for Personalized Medicine&lt;/h3&gt;

&lt;p&gt;As part of the MOLIT symposium, Christian Fegeler (MOLIT, Heilbronn) and Markus List organized a workshop on study designs for personalized medicine. The current premise is that present study designs are based on large groups of patients e.g. for testing the efficacy of medication. However, personalized medicine focuses on customized therapies for one single patient. During the workshop, we discussed how we can leverage the vast potential of molecular big data beyond the limited scope of clinical studies. Concepts like virtual cohorts may pave the way towards this in the future.&lt;/p&gt;

&lt;p&gt;More information: &lt;a href=&#34;https://molit.eu/en/projects/molit-symposium/program/&#34; target=&#34;_blank&#34;&gt;https://molit.eu/en/projects/molit-symposium/program/&lt;/a&gt;&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Big Data als Wegbereiter der Pr√§zisionsmedizin</title>
      <link>https://biomedical-big-data.de/talk/igld/</link>
      <pubDate>Tue, 15 Jan 2019 00:00:00 +0100</pubDate>
      
      <guid>https://biomedical-big-data.de/talk/igld/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
